Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability

Isocitrate dehydrogenase 1 (IDH1) mutations are common in gliomas, acute myeloid leukemia, and chondro‑ sarcoma. The mutation ‘hotspot’ is a single arginine residue, R132. The R132H mutant of IDH1 produces the 2‑hydroxy‑ glutarate (2‑HG) carcinogen from α‑ketoglutarate (α‑KG). The reduction of α‑KG induces the accumulation of hypoxia‑induc‑ ible factor‑1α subunit (HIF‑1α) in the cytosol, which is a predisposing factor for carcinogenesis. R132H is the most common IDH1 mutation in humans, but mutations at the R132 residue can also occur in tumor tissues of dogs. The current study reported the discovery of a novel Tyr208Cys (Y208C) mutation in canine IDH1 (cIDH1), which was isolated from 2 of 45 canine chondrosarcoma cases. As the genomic DNA isolated from chondrosarcoma tissue was mutated, but that isolated from blood was not, Y208C mutations were considered to be spontaneous somatic mutations. The isocitrate dehydro‑ genase activity of the Y208C mutant was attenuated compared with that of wild‑type (WT) cIDH1, but the attenuation of Y208C was less intense than that of the R132H mutation. The induction of HIF‑1α response element activity and cell reten‑ tion of HIF‑1α were not increased by Y208C overexpression. In silico and cell biological analysis of IDH1 dimerization revealed that the Y208C mutation, but not the R132H muta‑ tion, attenuated binding activity with WT cIDH1. These data suggested that the attenuation of dimerization by the Y208C mutation may cause tumorigenesis through different mecha‑ nisms other than via 2‑HG production by the IDH1 R132 mutation.